144 related articles for article (PubMed ID: 35291609)
1. The Impacts of Prepared Plasma-Activated Medium (PAM) Combined with Doxorubicin on the Viability of MCF-7 Breast Cancer Cells: A New Cancer Treatment Strategy.
Zahedian S; Hekmat A; Tackallou SH; Ghoranneviss M
Rep Biochem Mol Biol; 2022 Jan; 10(4):640-652. PubMed ID: 35291609
[TBL] [Abstract][Full Text] [Related]
2. Effects of cold atmospheric-pressure plasma in combination with doxorubicin drug against breast cancer cells in vitro and invivo.
Dezhpour A; Ghafouri H; Jafari S; Nilkar M
Free Radic Biol Med; 2023 Nov; 209(Pt 2):202-210. PubMed ID: 37890599
[TBL] [Abstract][Full Text] [Related]
3. The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells.
Czeczuga-Semeniuk E; Wołczyński S; Dabrowska M; Dziecioł J; Anchim T
Folia Histochem Cytobiol; 2004; 42(4):221-7. PubMed ID: 15704648
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
5. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
8. Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin.
Febriansah R; Putri DD; Sarmoko ; Nurulita NA; Meiyanto E; Nugroho AE
Asian Pac J Trop Biomed; 2014 Mar; 4(3):228-33. PubMed ID: 25182442
[TBL] [Abstract][Full Text] [Related]
9. Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines
Figueroa D; Asaduzzaman M; Young F
Biomed Res Int; 2019; 2019():6146972. PubMed ID: 30766885
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis Inducing Activity of Rhinacanthin-C in Doxorubicin-Resistant Breast Cancer MCF-7 Cells.
Chaisit S; Jianmongkol S
Biol Pharm Bull; 2021; 44(9):1239-1246. PubMed ID: 34471052
[TBL] [Abstract][Full Text] [Related]
11. Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress.
Yang Y; Chen Y; Zhang F; Zhao Q; Zhong H
Int J Hyperthermia; 2015; 31(5):498-506. PubMed ID: 25955015
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells.
Nurhayati IP; Khumaira A; Ilmawati GPN; Meiyanto E; Hermawan A
Asian Pac J Cancer Prev; 2020 May; 21(5):1259-1267. PubMed ID: 32458631
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
14. Newly Synthesized Doxorubicin Complexes with Selected Metals-Synthesis, Structure and Anti-Breast Cancer Activity.
Jabłońska-Trypuć A; Świderski G; Krętowski R; Lewandowski W
Molecules; 2017 Jul; 22(7):. PubMed ID: 28677642
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyl safflower yellow B combined with doxorubicin inhibits the proliferation of human breast cancer MCF-7 cells.
Lin K; Qin Z; Qu C; Chen X; Jiang Q; Li M; Zheng Q; Li D
Oncol Lett; 2021 May; 21(5):426. PubMed ID: 33850567
[TBL] [Abstract][Full Text] [Related]
16. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
17. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
[TBL] [Abstract][Full Text] [Related]
18. The Synergistic Anticancer Traits of Graphene Oxide Plus Doxorubicin Against BT474 and MCF7 Breast Cancer Stem Cells In Vitro.
Ebrahimi M; Teimouri M; Pooladi M
Appl Biochem Biotechnol; 2021 Nov; 193(11):3586-3601. PubMed ID: 34324153
[TBL] [Abstract][Full Text] [Related]
19. Plasma-activated medium induces A549 cell injury via a spiral apoptotic cascade involving the mitochondrial-nuclear network.
Adachi T; Tanaka H; Nonomura S; Hara H; Kondo S; Hori M
Free Radic Biol Med; 2015 Feb; 79():28-44. PubMed ID: 25433364
[TBL] [Abstract][Full Text] [Related]
20.
Tai X; Cai XB; Zhang Z; Wei R
Oncol Lett; 2016 Nov; 12(5):3701-3706. PubMed ID: 27900057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
